Parameter | Values | Description and references |
---|---|---|
Weibull survival model of PFS in the Control strategy | Scale = 0.1559; | [11] |
Shape = 1.045; | ||
r2 = 0.976 | ||
Weibull survival model of OS for supportive care | Scale = 0.04006; |  |
Shape = 1.156; | [20] | |
r2 = 0.9898 | ||
Weibull survival model of OS for 2nd-line chemotherapy | Scale = 0.03897; | [20] |
Shape = 1.509; | ||
r2 = 0.981 | ||
HR of PFS for the Gefitinib strategy in patients with an EGFR mutation | 0.17 (95% CI:0.07–0.42) | [11] |
Frequency of EGFR mutations | 50% (range: 8%–70%)* | [11] |
Proportion of patients receiving 2nd-line chemotherapy | 56.6% (range: 26%–72%)* | |
Frequency of follow-up | ||
 0–2 years | Once per four months | [26] |
 after 2 years | Once per year | [26] |
Probability of SAEs in the Gefitinib strategy | 7% (range: 5.25%–8.75%)* | [11] |
Probability of SAEs in the Control strategy | 3% (range: 2.25%–3.75%)* | [11] |
Probability of SAEs using platinum-based chemotherapy | 80% (range: 60%–100%)* | [27] |